<link>Opexa to Present at the Rodman & Renshaw 12th Annual Healthcare Conference on September 14, 2010
THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tovaxin®, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced that Neil K. Warma, Opexa’s President and Chief Executive Officer, will deliver a corporate presentation at the Rodman & Renshaw 12th Annual Healthcare Conference. The conference will be held September 12-15, 2010 at the New York Palace Hotel in New York City.
Opexa’s presentation will occur at 4:30 p.m. (EDT) on Tuesday, September 14, 2010 in the Hubbard Salon (5th Floor) of the New York Palace Hotel and will include an overview of the Company’s ongoing clinical development program for Tovaxin, the Company’s lead therapy for MS. The presentation will be webcasted and the link to access the audio webcast and presentation will be available at the Investor Relations page of the Company’s website at www.opexatherapeutics.com.